PDK4 and diffuse large B-cell lymphoma: Based on the results, PDK4, during the process of resistance to rituximab in DLBCL, could transcriptionally suppress the expression of CD20 by phosphorylating HDAC8, and there is an interaction between HDAC8 and CD20.